Our Antibody Drug Conjugates (ADCs) may serve as a highly effective treatment alternative to traditional chemotherapies.
We are using our proprietary discovery technology to build a pipeline of first-in-class ADCs targeting novel proteins.
This ADC program targets solid tumors and is in early IND-Enabling studies.
Details are forthcoming.
A highly targeted ADC may reduce side effects compared to conventional chemotherapies.
First-in-class therapies with new mechanisms of action, provides doctors and patients with new options for cancer treatment.
Provides potential treatment alternatives for solid tumors with significant unmet clinical need.
Learn about our SPARTA technology, a unique in vivo antibody selection and target discovery process that is advancing ADC development.